Axsome Therapeutics (AXSM) Misses Q4 EPS by 92c

Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($2.08), $0.92 worse than the analyst estimate of ($1.16). Revenue for the quarter came in at $71.53 million versus the consensus estimate of $68.83 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)
• Westinghouse said to seek over $50 billion valuation in planned IPO